Related Experiment Videos
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
P T Golumbek1, A J Lazenby, H I Levitsky
1Department of Medicine, Johns Hopkins University, Baltimore, MD 21205.
Abstract:
The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.
Insights
Genetically engineered tumors secreting interleukin-4 (IL-4) were rejected independently of T cells but induced systemic, CD8+ T cell-mediated immunity. This immunity eradicated established tumors, supporting gene-transfected tumor cells for cancer therapy.
Area of Science:
- Immunology
- Oncology
- Gene Therapy
Background:
- Antigen-specific antitumor immunity is crucial for effective cancer immunotherapy.
- Tumor rejection and subsequent systemic immunity are key goals in developing novel cancer treatments.
Purpose of the Study:
- To investigate the potential of engineering tumor cells to secrete interleukin-4 (IL-4) for inducing antitumor immunity.
- To evaluate the systemic and specific immune responses generated by IL-4 secreting tumor cells.
Main Methods:
- Murine renal cell tumor cells were genetically modified to secrete high doses of IL-4.
- Tumor rejection and systemic immunity in mice were assessed.
- The role of T cells and CD8+ T cells in mediating the immune response was analyzed.
Main Results:
- IL-4 secreting tumor cells were rejected in a T cell-independent manner.
- Rejection of IL-4 transfected tumors led to the development of T cell-dependent, tumor-specific systemic immunity.
- This systemic immunity was primarily mediated by CD8+ T cells and could cure established parental tumors.
Conclusions:
- Engineering tumor cells to secrete IL-4 can generate potent, tumor-specific systemic immunity.
- This approach holds promise as a novel modality for cancer therapy by leveraging the host's immune system.
- The study provides a strong rationale for using lymphokine gene-transfected tumor cells in cancer treatment strategies.